Biotech IPOs stayed at slow pace, but grew larger in the first quarter of 2026
BioPharma Dive
The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing what s been observed over a similar timeframe in prior years, according to
AZ considers filings for long-acting Strensiq follow-up
Pharmaphorum
AstraZeneca’s long-acting Strensiq follow-up efzimfotase alfa has hit the mark in children with rare disease HPP, but the data in adults is unclear.
S16 Ep40: FDA Approval Insights: Zongertinib for HER2 TKD-Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD
OncLive Podcast
In today’s episode, we spoke with Julia Rotow, MD, and Martin Dietrich, MD, PhD.
Blackstone closes $6.3B fund for life sciences investing
BioPharma Dive
It’s the biggest life sciences private fund ever raised, coming in nearly 40% larger than its Blackstone predecessor vehicle.
Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout
BioSpace
While tonlamarsen missed one of two co-primary endpoints, Kardigan says the drug has shown a clinically meaningful effect on blood pressure, supporting advancement into Phase 2b.
Biogen Bounces Back With FDA Nod for High-Dose Spinal Muscular Atrophy Drug
BioSpace
The FDA rejected the high-dose regimen of Spinraza in September last year due to manufacturing concerns.
Biogen’s Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline
BioSpace
William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results “another derisking step” for the company’s immunol
One in four diabetics has undiagnosed heart failure; study
Pharmaphorum
A study has found that undiagnosed heart failure can be detected in people with high-risk diabetes using a simple, GP-led care pathway.
The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments
Drug Channels
Three is still the magic number for pharmacy benefit managers (PBMs).
Amgen’s BiTE for lung cancer backed for EU approval
Pharmaphorum
Amgen’s fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.
Trustworthy AI in clinical oversight
BioPharma Dive
AI can accelerate clinical work and preserve traceability, but only if users can trust it.
Otsuka grows in neuroplastogens with $1.225bn Transcend buy
Pharmaphorum
Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.
Lilly puts up to $2.75bn into Insilico alliance
Pharmaphorum
Insilico has once again added to its roster of big pharma partners, signing a deal with Eli Lilly that includes a $115m upfront payment.
S16 Ep38: Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC
OncLive Podcast
In this podcast, experts Narjust Florez, MD, FASCO; David Carbone, MD, PhD; and Edward Garon, MD, MS; discuss the use of KRAS-, NRG1-, MET-, and ROS1-targeting agents to transform patient care in adva
Accord, Intas, and Bio-Thera File Four IPRs Against Janssen Golimumab Patents
Big Molecule Watch
On March 20, 2026, Accord BioPharma, Inc.
Otsuka picks up PTSD drug with $700M Transcend buy
BioPharma Dive
The buyout, which includes another $525 million in floated payouts, hands Otsuka a medicine it sees as a possibly paradigm-shifting therapy in psychiatry.
AstraZeneca lung drug gets ‘surprise’ win in COPD trials
BioPharma Dive
The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent.
Novartis targets Xolair successor in buyout of startup Excellergy
BioPharma Dive
Worth up to $2 billion, the deal is centered around a drug that could lead to faster and more complete control of allergic conditions than Novartis and Roche s popular medicine.
The Rare Journey Needs a Special Pharmacy Partner
Drug Channels
Today’s guest post is from Bansi Nagji, Chief Executive Officer at PANTHERx Rare.